3^rd LARIX INTERNATIONAL SUMMIT ON GASTROINTESTINAL DISEASES

LISGID 2026

We are excited to present the 3^rd Larix International Summit on Gastro Intestinal Diseases (LISGID 2026) scheduled on 05th - 08th April 2026. This distinguished event will bring Gastroenterologists, Medicine Specialists, General Practitioners, Clinical Researchers and Residents to discuss and deliver presentations, which includes topics such as Common Diseases of Gastro Intestinal Tract, Gastro Intestinal Endoscopy, Pancreatitis, Bowel Disorders, Colonoscopy, Liver Disorders, Gastro Intestinal Tract Cancer, ERCP, Gastrointestinal Bleeding, Gastroduodenal Diseases, Colorectal Cancer, Peptic Ulcer Disease. The scientific sessions of this summit are comprised of keynote lectures, hands-on workshops, case-based video presentations, peer-reviewed poster presentations and much more!

ABOUT LARIX INTERNATIONAL

Larix International is a publishing and conference planning organization committed to the global dissemination of scientific knowledge. Doctors, engineers, and scientists who were passionate about scientific advancements and wanted to produce high-caliber scientists and technologists co-founded Larix International. Through the development of an executive network of strategic alliances, we are able to provide real-time innovations by assisting our international researchers in fulfilling their vision, mission, and long-term strategic objectives.

THEMES OF THE SUMMIT

Session # 01: Common Diseases of Gastro Intestinal Tract

·       Sub-Session 1: Navigating the evolving landscape of GERD: From pathophysiology to precision therapy.

·       Sub-Session 2: Innovation and balance: Latest insights and clinical applications of acid-suppressive therapies.

·       Sub-Session 3: Innovative approaches in functional dyspepsia: From mechanisms to multimodal management.

·       Sub-Session 4: Diagnostic and therapeutic approaches to refractory functional gastrointestinal symptoms.

Session # 02: Gastro Intestinal Endoscopy

·       Sub-Session 1: Precision diagnostics in upper GI endoscopy: The role of artificial intelligence.

·       Sub-Session 2: Clinical practice guidelines for upper GI endoscopy: Case based learning.

·       Sub-Session 3: Advancing therapeutic endoscopy techniques.

·       Sub-Session 4: Recent updates in the endoscopic diagnosis and management of pancreatic cysts.

Session # 03: Pancreatitis

·       Sub-Session 1: Autoimmune pancreatitis: Cornerstones and future perspectives.

·       Sub-Session 2: Managing complications of chronic pancreatitis: a guide for the gastroenterologist.

·       Sub-Session 3: The interaction of microbiome and pancreas in acute pancreatitis.

·       Sub-Session 4: Groove pancreatitis: from enigma to future directions.

Session # 04: Bowel Disorders

·       Sub-Session 1: Advancing IBD care: Translating research into clinical practice.

·       Sub-Session 2: Innovations in endoscopic management of IBD.

·       Sub-Session 3: Comprehensive strategies in IBS management: From pathophysiology to practice.

·       Sub-Session 4: Emerging trends in constipation treatment: From microbiota to modern therapeutics.

Session # 05: Colonoscopy

·       Sub-Session 1: Latest advances in diagnostic and therapeutic colonoscopy for challenging situations.

·       Sub-Session 2: Adverse events related to colonoscopy: Global trends and future challenges.

·       Sub-Session 3: Optimization of colonoscopy quality: Comprehensive review of the literature and future perspectives.

·       Sub-Session 4: AI for colonoscopy and intestinal diseases: The road ahead.

Session # 06: Liver Disorders

·       Sub-Session 1: Special considerations for liver diseases in distinct conditions.

·       Sub-Session 2: Biomarkers for diagnosis, treatment response, and prognosis in liver diseases.

·       Sub-Session 3: Guidelines and evidence-based recommendations in liver disease management.

·       Sub-Session 4: Early predictors of hepatitis B relapse after antiviral cessation.

Session # 07: Gastro Intestinal Tract Cancer

·       Sub-Session 1: Novel biomarkers and strategies in early diagnosis of gastrointestinal cancers.

·       Sub-Session 2: Pancreatic ductal adenocarcinoma: Insights from genomics to clinical implications.

·       Sub-Session 3: Focused management strategies in gastrointestinal cancer.

·       Sub-Session 4: Innovative strategies in gastroesophageal cancer therapy: Precision medicine, resistance, and emerging technologies. 

Session # 08: ERCP

·       Sub-Session 1: Ensuring safety and effectiveness in ERCP: Case-based approaches with technical insights.

·       Sub-Session 2: ERCP in the management of biliary complications after cholecystectomy.

·       Sub-Session 3: Clinical practice guideline for post-ERCP pancreatitis.

·       Sub-Session 4: Current challenges in pediatric ERCP.         

Session # 09: Gastrointestinal Bleeding

·       Sub-Session 1: Managing antiplatelet and anticoagulation: Therapy in the peri-endoscopic period.

·       Sub-Session 2: Management of nonvariceal upper GI bleeding: Choosing the right tool.

·       Sub-Session 3: Lower GI bleeding: Role of the endoscopist and a treatment algorithm.

·       Sub-Session 4: Investigating and managing small bowel bleeding.

Session # 10: Gastroduodenal Diseases

·       Sub-Session 1: Autoimmune gastritis, eosinophilic gastroduodenitis:New advances in diagnosis and therapy.

·       Sub-Session 2: The evolution of gastroparesis as a sensorimotor disorder: It's on the spectrum.

·       Sub-Session 3: Artificial nutrition support in disorders of gut-brain interaction: What, when, why not?

·       Sub-Session 4: Complex case discussion.      

Session # 11: Colorectal Cancer

·       Sub-Session 1: Exploring the latest advances in colorectal cancer prevention and screening.

·       Sub-Session 2: Optimal treatment strategies for rectal cancer.

·       Sub-Session 3: Current insights and future directions in colorectal neoplasia: Pathogenesis, detection and therapy.

·       Sub-Session 4: Genetic and biological hallmarks of colorectal cancer.      

Session # 12: Peptic Ulcer Disease

·       Sub-Session 1: The shifting etiology of PUD: Moving beyond H. pylori and NSAIDs to include idiopathic ulcers.

·       Sub-Session 2: Global trends in PUD burden: Analyzing declining prevalence alongside rising complications in specific regions

·       Sub-Session 3: Confronting antimicrobial resistance: Updated, effective, and evidence-based quad therapy for H. pylori eradication.

·       Sub-Session 4: Management of refractory PUD: Treatment approaches for ulcers that fail to heal after standard therapy.

CALL FOR ABSTRACT

You are invited to submit your abstracts above topics. Based on the review of scientific committee, a limited number of abstracts will be selected for display and/or oral presentation.

Among the accepted abstracts, three principal authors will get the opportunity to be included in main scientific session as keynote speaker. Please read this Call for Abstracts information carefully before accessing the abstract submission form.

KEY DATES

Early Bird Registration: 30^th December, 2025

Abstract Submission Deadline: 25^th March 2026

Summit Date: 05 - 08^th April, 2026

WHO CAN ATTEND?

Gastroenterologists, Medicine Specialists, General Practitioners, Clinical Researchers, and Residents.